Program
HBI-002
A development code.
Its studies are mostly in Anemia, Sickle Cell · Parkinson Disease, led by Hillhurst Biopharmaceuticals.
Furthest: phase 2, since Nov 10, 20233 company-led studies, 1 open or runningNext primary completion: Dec 31, 2026 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Hillhurst Biopharmaceuticals | 31 open or running | phase 2since Nov 10, 2023 | Apr 22, 2019 | Dec 31, 2026phase 2 · NCT07005180 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Apr 22, 2019First study: phase 1 study in Anemia, Sickle CellFirst studyNCT03926819 · 20 enrolled · United States
- Nov 10, 2023Phase 2 study in Anemia, Sickle CellNCT06144749 · 13 enrolled · Panama
- Feb 28, 2025Phase 2 study in Parkinson DiseaseNCT07005180 · 36 planned · United States
Ahead
- Dec 31, 2026Primary completion: phase 2 study in Parkinson DiseaseNCT07005180
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07005180Parkinson Disease · United States | 2 | Recruiting | Dec 31, 2026 | 36 |
| NCT06144749Anemia, Sickle Cell · Panama | 2 | Completed | Jun 30, 2026 | 13 |
| NCT03926819Anemia, Sickle Cell · United States | 1 | Completed | Apr 26, 2023 | 20 |
How it is read
Names in the registry
- “HBI-002”, 3 entries
Codes read as this program: HBI002.
Conditions, from the studies’ own filings
- Anemia, Sickle Cell, 2 studies
- Parkinson Disease, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.